AEHR TEST SYSTEMS
AEHRdata completeness 88%17 fiscal years on fileAEHR TEST SYSTEMS earns about 19% on invested capital, but has diluted owners by 10% over 5 years — worth asking whether the growth reaches owners. The applicable estimate puts fair value near $3.19 a share.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|
| Revenue | $50.8M1 | $65M2 | $66.2M3 | $59M3 | $50M3 |
| Net income | $9.45M4 | $14.6M5 | $33.2M6 | −$3.91M6 | −$7.13M6 |
| Operating cash flow | $1.51M7 | $10M8 | $1.76M9 | −$7.4M9 | −$3.31M9 |
| Capital expenditure | $416,00010 | $1.36M11 | $749,00012 | $4.99M12 | $2.07M12 |
| Free cash flow (derived) | $1.09M7 | $8.65M8 | $1.01M9 | −$12.4M9 | −$5.38M9 |
| Total debt | $013 | — | — | — | — |
| Cash & equivalents | $31.5M14 | $30.1M15 | $49.2M16 | $24.5M17 | $116.4M17 |
| Diluted shares | 27.8M | 29.2M | 29.6M | 29.6M | 30.7M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $71.57 of net worth that earned you −$2.32 and generated −$1.75 of cash last year.
It earned an average 19% on invested capital over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is up 10% over 5 years — owners have been diluted. Worth asking what they got for it.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
assumptions (8)
- riskFreeRate4.7%
- equityRiskPremium5.0%
- beta100.0%
- equityWeight85.0%
- costOfDebtSpread1.5%
- taxRate21.0%
- normalizedEarnings$9.45M
- growthAssumed0.0%
Different models answer different questions — which to trust when →
- 10-K · period ending 2022-05-31 · accession 0001654954-24-009642 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-05-31 · accession 0001654954-25-008553 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2024-05-31 · accession 0001654954-26-006919 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-05-31 · accession 0001654954-24-009642 (NetIncomeLoss)
- 10-K · period ending 2023-05-31 · accession 0001654954-25-008553 (NetIncomeLoss)
- 10-K · period ending 2024-05-31 · accession 0001654954-26-006919 (NetIncomeLoss)
- 10-K · period ending 2022-05-31 · accession 0001654954-24-009642 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-05-31 · accession 0001654954-25-008553 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-05-31 · accession 0001654954-26-006919 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-05-31 · accession 0001654954-24-009642 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-05-31 · accession 0001654954-25-008553 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2024-05-31 · accession 0001654954-26-006919 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-05-31 · accession 0001654954-22-011877 (LongTermDebtCurrent)
- 10-K · period ending 2022-05-31 · accession 0001654954-23-011271 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-05-31 · accession 0001654954-24-009642 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-05-31 · accession 0001654954-25-008553 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2025-05-30 · accession 0001654954-26-006919 (CashAndCashEquivalentsAtCarryingValue)